Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | UGCG | Q16739 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1935743 | 0.82 | OPRK1 (0.56) | OPRK1OPRM1CYP3A4CYP2D6TSHR | |
| SCHEMBL16633980 | 0.82 | ALDH1A1 (0.41) | EPHX2 | |
| SCHEMBL16634078 | 0.81 | EPHX1 (0.40) | SLC6A4SLC6A2EPHX2 | |
| SCHEMBL16633204 | 0.80 | MMP2 (0.40) | SLC6A4SLC6A2OPRM1 | |
| SCHEMBL16633600 | 0.79 | MMP2 (0.46) | OPRK1OPRM1MEN1KMT2A | |
| SCHEMBL16632995 | 0.79 | EPHX1 (0.41) | SLC6A4SLC6A2EPHX2 | |
| SCHEMBL16633172 | 0.78 | ALDH1A1 (0.38) | EPHX2 | |
| SCHEMBL16633428 | 0.78 | ALDH1A1 (0.38) | SLC6A4SLC6A2OPRM1CYP2C19EPHX2 | |
| SCHEMBL16633307 | 0.78 | ALDH1A1 (0.38) | OPRM1EPHX2 | |
| SCHEMBL16563309 | 0.74 | UGCG (0.52) | SLC6A4SLC6A2UGCGOPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469637-B2 | Nitrogenated heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-18 | — | — | US | disclosed |
| US-20150105373-A1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105373-A1 | NITROGENATED HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | SLC6A4 338/4885SLC6A2 38/4885UGCG 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.